Literature DB >> 32978257

Human pancreatic cancer cells under nutrient deprivation are vulnerable to redox system inhibition.

Takefumi Onodera1, Isao Momose2, Hayamitsu Adachi1, Yohko Yamazaki1, Ryuichi Sawa3, Shun-Ichi Ohba1, Manabu Kawada1.   

Abstract

Large regions in tumor tissues, particularly pancreatic cancer, are hypoxic and nutrient-deprived because of unregulated cell growth and insufficient vascular supply. Certain cancer cells, such as those inside a tumor, can tolerate these severe conditions and survive for prolonged periods. We hypothesized that small molecular agents, which can preferentially reduce cancer cell survival under nutrient-deprived conditions, could function as anticancer drugs. In this study, we constructed a high-throughput screening system to identify such small molecules and screened chemical libraries and microbial culture extracts. We were able to determine that some small molecular compounds, such as penicillic acid, papyracillic acid, and auranofin, exhibit preferential cytotoxicity to human pancreatic cancer cells under nutrient-deprived compared with nutrient-sufficient conditions. Further analysis revealed that these compounds target to redox systems such as GSH and thioredoxin and induce accumulation of reactive oxygen species in nutrient-deprived cancer cells, potentially contributing to apoptosis under nutrient-deprived conditions. Nutrient-deficient cancer cells are often deficient in GSH; thus, they are susceptible to redox system inhibitors. Targeting redox systems might be an attractive therapeutic strategy under nutrient-deprived conditions of the tumor microenvironment.
© 2020 Onodera et al.

Entities:  

Keywords:  auranofin; cancer therapy; chemical biology; drug discovery; drug screening; glutathione; metabolism; oxidation reduction (redox); oxidative stress; papyracillic acid; penicillic acid; redox regulation; thioredoxin

Mesh:

Substances:

Year:  2020        PMID: 32978257      PMCID: PMC7864064          DOI: 10.1074/jbc.RA120.013893

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  56 in total

1.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

Review 2.  Redox Signaling Mediated by Thioredoxin and Glutathione Systems in the Central Nervous System.

Authors:  Xiaoyuan Ren; Lili Zou; Xu Zhang; Vasco Branco; Jun Wang; Cristina Carvalho; Arne Holmgren; Jun Lu
Journal:  Antioxid Redox Signal       Date:  2017-05-18       Impact factor: 8.401

3.  Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy.

Authors:  K Izuishi; K Kato; T Ogura; T Kinoshita; H Esumi
Journal:  Cancer Res       Date:  2000-11-01       Impact factor: 12.701

Review 4.  The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.

Authors:  J M Brown; A J Giaccia
Journal:  Cancer Res       Date:  1998-04-01       Impact factor: 12.701

Review 5.  AKT/PKB Signaling: Navigating the Network.

Authors:  Brendan D Manning; Alex Toker
Journal:  Cell       Date:  2017-04-20       Impact factor: 41.582

6.  Depiction of metabolome changes in histidine-starved Escherichia coli by CE-TOFMS.

Authors:  Yoshiaki Ohashi; Akiyoshi Hirayama; Takamasa Ishikawa; Seira Nakamura; Kaori Shimizu; Yuki Ueno; Masaru Tomita; Tomoyoshi Soga
Journal:  Mol Biosyst       Date:  2007-11-15

Review 7.  Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

Authors:  Dunyaporn Trachootham; Jerome Alexandre; Peng Huang
Journal:  Nat Rev Drug Discov       Date:  2009-05-29       Impact factor: 84.694

8.  Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy.

Authors:  Cigall Kadoch; Diana C Hargreaves; Courtney Hodges; Laura Elias; Lena Ho; Jeff Ranish; Gerald R Crabtree
Journal:  Nat Genet       Date:  2013-05-05       Impact factor: 38.330

Review 9.  Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer.

Authors:  John P Duffy; Guido Eibl; Howard A Reber; Oscar J Hines
Journal:  Mol Cancer       Date:  2003-01-22       Impact factor: 27.401

10.  Pancreatic adenocarcinomas with mature blood vessels have better overall survival.

Authors:  Eriko Katsuta; Qianya Qi; Xuan Peng; Steven N Hochwald; Li Yan; Kazuaki Takabe
Journal:  Sci Rep       Date:  2019-02-04       Impact factor: 4.379

View more
  3 in total

1.  Eukaryotic initiation factor 2 signaling behind neural invasion linked with lymphatic and vascular invasion in pancreatic cancer.

Authors:  Taiichi Wakiya; Keinosuke Ishido; Norihisa Kimura; Hayato Nagase; Tadashi Yoshizawa; Satoko Morohashi; Hiroaki Fujita; Taishu Kanda; Yota Tatara; Junji Saruwatari; Hiroshi Kijima; Kenichi Hakamada
Journal:  Sci Rep       Date:  2021-10-27       Impact factor: 4.379

Review 2.  Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness.

Authors:  Tania Gamberi; Giovanni Chiappetta; Tania Fiaschi; Alessandra Modesti; Flavia Sorbi; Francesca Magherini
Journal:  Med Res Rev       Date:  2021-12-01       Impact factor: 12.388

3.  Rewired Cellular Metabolic Profiles in Response to Metformin under Different Oxygen and Nutrient Conditions.

Authors:  Shan Liu; Jumpei Washio; Satoko Sato; Yuki Abiko; Yuta Shinohara; Yuri Kobayashi; Haruki Otani; Shiori Sasaki; Xiaoyi Wang; Nobuhiro Takahashi
Journal:  Int J Mol Sci       Date:  2022-01-17       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.